ArticleFrontiers in public health2025
Who benefits? Health equity and the Translational Science Benefits Model.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Road from Science to Health: The Importance of Designing For, Measuring, and Communicating Impact in Public Health.Annual review of public health · 2026Review
- Measuring the aggregated impact of research: Establishing criteria for coding Translational Science Benefits Model data.Journal of clinical and translational science · 2025Article
- The translational science promotion and research capacity (T-SPARC) framework: Developing institutional capacity for translational science.Journal of clinical and translational science · 2025Article
- Taking the Translational Science Benefits Model from concept to operationalization: opportunities and challenges in defining impact using the Translational Science Benefits Model.Frontiers in public health · 2025Article
- Application of a Conceptual Model for Translational Science Impact.Journal of clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evaluating the impacts of translational science is crucial for demonstrating the quality, relevance, and societal benefits of research. This paper presents current results of efforts to expand the Translational Science Benefits Model (TSBM), a framework and toolkit originally developed at Washington University in St. Louis with 30 specific, real-world benefits across clinical, community, economic, and policy domains. In response to a growing emphasis on health and social equity, we have refined the TSBM to better address and integrate ideas of fairness and justice. Methods: Our methods included a literature scan to identify health equity gaps in the framework, community listening sessions in St. Louis, MO, and Madison, WI, and thematic analysis to incorporate equity into the TSBM. Results: The results introduce new dimensions within the existing TSBM domains that include 10 new benefits, all emphasizing themes of trust, power, and access. Discussion: Our aim is to enhance the relevance and utility of the framework and tools to researchers, practitioners, and those affected by implementations of findings from translational science and research. The integration of equity into the TSBM supports continued growth in the number of users and uses of the framework and toolkit to demonstrate health and social impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.